NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization27,500 mln
Float133 mln
Earnings Date10/29/2026
EPS
5.73
Stretched
P / E
38.22
Overvalued
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-1.87
Caution advised
1-Year Forecast
428
Transformational upside
Relative Strength
5
/ 100
Severely lagging
Business Description
Alnylam Pharmaceuticals is a Cambridge, Massachusetts-based biotech company founded in 2002 that uses RNA interference technology to develop treatments for serious and rare diseases. The company already sells several approved medicines targeting conditions such as hereditary amyloidosis, high cholesterol, hemophilia, and rare liver disorders, while advancing a broad pipeline of experimental drugs aimed at heart disease, neurological conditions, metabolic disorders, and more. Alnylam works alongside major pharmaceutical partners including Novartis, Roche, Sanofi, and Regeneron to bring its science to patients across the United States and worldwide.
